Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD3161 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 150 μL intradermal injection of 1 μmol/L AZD3161 |
| 2 | EXPERIMENTAL | 150 μL intradermal injection of 6 μmol/L AZD3161 |
| 3 | EXPERIMENTAL | 150 μL intradermal injection of 30 μmol/L AZD3161 |
| 4 | ACTIVE_COMPARATOR | 150 μL intradermal injection of 10 mg/mL Lidocaine |
| 5 | PLACEBO_COMPARATOR | 150 μL intradermal injection of AZD3161 placebo |
| Name | Type | Description |
|---|---|---|
| AZD3161 | DRUG | Single dose, intradermal injection |
| Lidocaine | DRUG | Single dose, intradermal injection |
| AZD3161 Placebo | DRUG | - |
Inclusion Criteria: * Healthy Caucasian male and female volunteers aged 18 to 55 years inclusive with suitable veins for venepuncture * The subject belongs to skin type II or III according to Fitzpatrick skin type scale * Females must have a negative pregnancy test at screening and at admission, mu...
AZD3161 is an investigational small molecule being developed for peripheral neuropathic pain. It has been studied in a Phase 1 clinical trial involving healthy volunteers, with the trial also assessing effects related to nociceptive pain. The drug is administered via intradermal injection.
The molecular target of AZD3161 has not been disclosed. The drug is a small molecule in development for peripheral neuropathic pain, and its mechanism of action has not been publicly specified in available clinical trial information.
AZD3161 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is currently in Phase 1 clinical development for peripheral neuropathic pain.
AZD3161 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains in early-stage clinical testing for peripheral neuropathic pain.
AZD3161 has been studied in one completed Phase 1 trial, NCT01240148. This randomized, double-blind, placebo-controlled study enrolled 26 healthy volunteers in the United Kingdom to evaluate the drug's effect on quantitative sensory testing in normal and ultraviolet-C exposed skin.
No alternative names for AZD3161 have been disclosed. The drug is identified solely by its development code AZD3161 in clinical trial records, and no other names or aliases have been publicly associated with it.